Johan Israelian | Targeted Protein Degradation Symposium 2022

"We were looking at a target that there was no inhibitor in the market or in literature. So we had to design these assays from scratch and Promega Application Scientists were critical in helping us go in the right direction."

Johan Israelian from the University of Toronto shares his experience in working with our custom assay service team to develop new assays needed for rare disease research, as well as accelerating their drug development workflows by integrating existing products.